PG 103

Drug Profile

PG 103

Alternative Names: PG103

Latest Information Update: 12 Feb 2016

Price : $50

At a glance

  • Originator Cytopathfinder
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Pancreatitis

Most Recent Events

  • 12 Feb 2016 PG 103 is available for licensing as of 12 Feb 2016.
  • 30 Jun 2014 Clinical trials in Pancreatitis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top